Nonylphenol-induced hyperadrenalism can be reversed/alleviated by inhibiting of 11-β hydroxysteroid dehydrogenase type 1

被引:3
|
作者
Chang, Ling-Ling [1 ]
Wun, Wan-Song A. [2 ]
Wang, Paulus S. [3 ,4 ,5 ,6 ]
机构
[1] Chinese Culture Univ, Dept Chem & Mat Engn, Taipei 11114, Taiwan
[2] Houston Fertil Specialists, Houston, TX 77054 USA
[3] Natl Yang Ming Univ, Sch Med, Dept Physiol, Taipei 11221, Taiwan
[4] Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan
[5] China Med Univ Hosp, Med Ctr Aging Res, Taichung 40402, Taiwan
[6] Asia Univ, Dept Biotechnol, Taichung 41354, Taiwan
关键词
NP; PF915275; Adipogenesis; 11; beta-HSD1; Hyperadrenalism; Metabolic syndrome; INSULIN-RESISTANCE; METABOLIC SYNDROME; GLUCOSE-TRANSPORTER; PLASMA ADIPONECTIN; RAT; SECRETION; EXPOSURE; SENSITIVITY; OBESITY; MODEL;
D O I
10.1016/j.etap.2016.03.019
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
We previously observed that nonylphenol (NP) exposure during development resulted in increases in body weight and hyperadrenalism in adult male offspring. The mechanism of hyperadrenalism includes the primary activation of the adrenal gland and the conversion of inactive glucocorticoids to active glucocorticoids by 11 beta-HSD1. The inhibition of 11 beta-HSD1 is investigated as a new therapeutic approach. This study examined the effect of PF915275 (a selective 11 beta-HSD1 inhibitor) on hyperadrenalism and adipogenesis in male rats exposed to NP during development. The results showed that treatment with the 11 beta-HSD1 inhibitor PF915275 reversed/alleviated NP-induced hyperadrenalism via the following mechanisms: (1) decreasing serum corticosterone, 11 beta-hydroxylase, and aldosterone synthase levels; (2) significantly increasing PPAR alpha protein and mRNA expression. In adipose tissue, NP significantly increased PPAR gamma mRNA expression, whereas PF915275 significantly decreased the level of mRNA expression; and (3) the expression of key regulators/enzymes in the adipogenesis metabolic pathway was also modulated. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [41] The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy
    Rosenstock, Julio
    Banarer, Salomon
    Fonseca, Vivian A.
    Inzucchi, Silvio E.
    Sun, William
    Yao, Wenqing
    Hollis, Gregory
    Flores, Robert
    Levy, Richard
    Williams, William V.
    Seckl, Jonathan R.
    Huber, Reid
    DIABETES CARE, 2010, 33 (07) : 1516 - 1522
  • [42] 11β-Hydroxysteroid Dehydrogenase Type 1 Regulates Glucocorticoid-Induced Insulin Resistance in Skeletal Muscle
    Morgan, Stuart A.
    Sherlock, Mark
    Gathercole, Laura L.
    Lavery, Gareth G.
    Lenaghan, Carol
    Bujalska, Iwona J.
    Laber, David
    Yu, Alice
    Convey, Gemma
    Mayers, Rachel
    Hegyi, Krisztina
    Sethi, Jaswinder K.
    Stewart, Paul M.
    Smith, David M.
    Tomlinson, Jeremy W.
    DIABETES, 2009, 58 (11) : 2506 - 2515
  • [43] 11β-Hydroxysteroid Dehydrogenase Type 1 in Obese Subjects With Type 2 Diabetes Mellitus
    Li, Xia
    Wang, Jingli
    Yang, Qin
    Shao, Shiying
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2017, 354 (04): : 408 - 414
  • [44] Adipose tissue expression of 11β-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity
    Espindola-Antunes, Daniela
    Kater, Claudio E.
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2007, 51 (08) : 1397 - 1403
  • [45] Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity
    Liu, Juan
    Wang, Long
    Zhang, Aisen
    Di, Wenjuan
    Zhang, Xiao
    Wu, Lin
    Yu, Jing
    Zha, Juanmin
    Lv, Shan
    Cheng, Peng
    Hu, Miao
    Li, Yujie
    Qi, Hanmei
    Ding, Guoxian
    Zhong, Yi
    ENDOCRINE JOURNAL, 2011, 58 (03) : 199 - 209
  • [46] 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors as Promising Therapeutic Drugs for Diabetes: Status and Development
    Ge, R.
    Huang, Y.
    Liang, G.
    Li, X.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (05) : 412 - 422
  • [47] Regulatory Effect of Common Promoter Polymorphisms on the Expression of the 11β-Hydroxysteroid Dehydrogenase Type 1 Gene
    Ku, Yun Hyi
    Koo, Bo Kyung
    Kwak, Soo Heon
    Cho, Young Min
    Shin, Hyoung Doo
    Lee, Hong Kyu
    Kim, Yeonjung
    Choi, Jung-Won
    Oh, Bermseok
    Park, Kyong Soo
    HORMONE RESEARCH, 2009, 72 (01) : 25 - 32
  • [48] In Vivo Activity of 11β-Hydroxysteroid Dehydrogenase Type 1 in Man: Effects of Prednisolone and Chenodesoxycholic Acid
    Diederich, S.
    Quinkler, M.
    Mai, K.
    Schoeneshoefer, M.
    Baehr, V.
    Pfeiffer, A.
    Oelkers, W.
    Eigendorff, E.
    HORMONE AND METABOLIC RESEARCH, 2011, 43 (01) : 66 - 71
  • [49] Physiological roles of 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase
    White, Perrin C.
    Rogoff, Daniela
    McMillan, D. Randy
    CURRENT OPINION IN PEDIATRICS, 2008, 20 (04) : 453 - 457
  • [50] Synthesis and optimization of picolinamide derivatives as a novel class of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors
    Ryu, Je Ho
    Kim, Shinae
    Lee, Jung A.
    Han, Hye Young
    Son, Hyun Joo
    Lee, Hyun Jung
    Kim, Yong Hyuk
    Kim, Jae-Sun
    Park, Hyeung-geun
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (08) : 1679 - 1683